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Glomerular macrophage phagocytic activity in experimental immune
complex glomerulonephritis. In rats with the proliferative immune
complex glomerulonephritis of chronic serum sickness, kidney function
deteriorates in three clearly distinguishable and discrete stages: mild,
moderate and severe. The macrophage component of glomerular in-
flammation in each stage is also quantitatively and qualitatively distinct,
with abnormal phenotypic markers appearing in the moderate stage and
increasing in the severe stage. To determine whether there were distinct
functional differences among macrophages from the three stages, Fcy
receptor-mediated phagocytic capacity was measured. The phagocytic
capacity of glomerular macrophages increased significantly in the
moderate stage, then significantly decreased, as rats progressed to
severe chronic serum sickness. This decline in phagocytic function was
not associated with a decrease in the expression of Fcy receptors on the
glomerular macrophage cell surface. Furthermore, the phagocytic func-
tion of peritoneal macrophages from rats with severe chronic serum
sickness was not impaired. Whether or not this attenuation of glomer-
ular macrophage phagocytic capacity is the cause, or result, of renal
disease progression remains unclear. It may indicate a potentially
protective role for intraglomerular macrophages, and can serve as an
additional functional marker of disease progression.
Chronic serum sickness in rats is a model of human prolifer-
ative glomerulonephritis that allows for the study of the rela-
tionship between kidney pathophysiology and immunopathol-
ogy [1]. Three discrete stages of nephritis have been defined.
Those stages, designated mild, moderate and severe, are each
clearly distinguishable by characteristic immunopathologic and
pathophysiologic features [2—6]. A significant glomerular hyper-
cellularity develops in the moderate stage that is largely attrib-
utable to the accumulation of macrophages, some of which
express abnormal phenotypic markers [6]. During the severe
stage of nephritis, which is characterized by an irreversible
decline in glomerular filtration rate [2], the number of glomer-
ular macrophages and the percentage expressing abnormal
phenotypic markers, increases even further [2, 4, 6]. There is
substantial evidence that macrophages contribute significantly
to the pathogenesis of both acute and chronic proliferative
immune complex glomerulonephritis [7—13]. The phagocytic
capacity of glomerular macrophages has been demonstrated by
their ability to ingest various materials, including preformed
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immune complexes [14], ferritin [15], immunoglobulin aggre-
gates [16] and colloidal carbon [17]. Additionally, in animal
models of diffuse proliferative glomerulonephntis, it has been
shown that glomerular macrophages play a predominant role in
the phagocytosis of circulating immune complexes [16, 17].
This phagocytic function may contribute to renal tissue damage
and disease progression [18], but may also have a protective
role. Persistence of glomerular immune complexes, whether
secondary to a decrease in glomerular macrophage numbers in
one animal model [19], or impaired epithelial cell endocytosis in
another [20], has been postulated to contribute to the progres-
sion of the lesions of immune complex glomerulonephritis. We
wished to determine if the changes in macrophage phenotype
that accompany the progression of immune complex nephritis
were correlated with functional changes in those cells. For that
reason, Fcy receptor-mediated phagocytosis was measured in
vitro at each of the three stages of chronic serum sickness; the
function of glomerular macrophages was compared to that of
the resident peritoneal macrophages from normal rats as well as
that of peritoneal macrophages from rats in each of the stages of
chronic serum sickness. A specific association between glomer-
ular macrophage phagocytic function and disease progression
has not previously been demonstrated.
Methods
Induction and monitoring of chronic serum sickness
Female LEW rats (Charles River Breeding Laboratories),
weighing 125 to 150 g received four subcutaneous injections of
3 mg of bovine serum albumin (BSA) in incomplete Freund's
adjuvant at two week intervals as previously described [1, 21],
until precipitating antibodies to BSA with titers (log2)  16were
produced. Gradually increasing amounts of daily intravenous
BSA injections were given until the rats tolerated a single daily
intravenous injection of 2 mg BSA in 0.4 ml isotonic saline [1,
21]. Urine samples were collected at least twice per week from
animals kept overnight (16 hr) in metabolism cages. At the end
of each urine collection period, 100 .d of blood were obtained
from the tail vein. Protein, albumin, creatinine and sodium
concentrations in urine and plasma were measured as previ-
ously described [2, 4].
The criteria for distinguishing the stages of chronic serum
sickness were as previously described (Table 1) [2—6]. Briefly,
normal protein excretion ( 25 mg124 hr), normal creatinine
clearance ( 0.50 ml/min x 100 g body wt) and normal sodium
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Table 1. Some key features of chronic serum sickness
glomerulonephritis
Mild Moderate Severe






Total 8 25 50
ED1+a 8 23 47
ED2+a 0 0 5
ED3+a 0 9 41
Number of T cells per 0 2—4 0
glomerular cross section






a The monoclonal antibody EDI recognizes monocytes and most
macrophages; ED2 recognizes many mature tissue macrophages; ED3
is a macrophage antigen normally expressed only in lymphoid tissue
[25].
excretion ( 0.25 mEqI24 hr x 100 g body wt) were character-
istic of the mild stage. The moderate stage begins with the
sudden onset of proteinuria, while normal creatinine clearance
was maintained. The severe stage begins with an abrupt de-
crease in both creatinine clearance (0.25 mllmin) and sodium
excretion ( 0.20 mEq/24 hr), accompanied by further in-
creases in urinary protein excretion. In addition to these
pathophysiologic parameters, there are also quantitative and
phenotypic changes in the glomerular macrophage population
that distinguish each stage of nephritis (Table 1) [61.
Buffers and media
Isotonic veronal buffered saline (VBS), 0.01 M EDTA buffer
and dextrose veronal buffered saline (DVBS) were prepared as
previously described [22, 23]. Hanks balanced salt solution with
and without calcium and magnesium (HBSS and HBSS,
respectively) and RPMI 1640 were obtained from GIBCO
(Grand Island, New York, USA). Hypotonic saline buffer
containing 0.66 M ammonium chloride, 3.7 x i0 M potassium
carbonate and 1.1 >( lO M EDTA (lysing buffer) was prepared
in our laboratory.
Preparation of opsonized sheep erythrocytes
Sheep erythrocytes (E) were washed with 0.01 M EDTA
buffer and VBS buffer before suspension in VBS at 1 x io
cells/mi. A portion of E was suspended in DVBS and a 1:100
dilution of rabbit anti-sheep IgG (Diamedix, Miami, Florida,
USA) or rat anti-sheep IgG (provided by Dr. William Cham-
bers, Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania,
USA) was added followed by a 15 minute incubation at 37°C to
form opsonized sheep erythrocytes (EIgG). These cells were
then washed three times in DVBS. Both E and EIgG were
resuspended in DVBS at 1.5 x 108 cells/ml for use in phagocy-
tosis and rosetting assays.
Isolation of glomerular macrophages
Glomerular macrophages were isolated from the kidneys of
normal, age-matched control rats and from each stage of
chronic serum sickness glomerulonephritis, as previously de-
scribed [24]. Briefly, rat kidneys were perfused in situ with
sterile PBS, then removed. Glomerular isolation was accom-
plished by compressing slices of cortex through 60-, 100- and
200-mesh steel sieves. Cell dissociation was accomplished by a
three-stage procedure. First the glomeruli were incubated for 20
minutes at 37°C with shaking, in a cocktail consisting of 5 mg
trypsin type II, 10 mg collagenase type I and 1 mg deoxyribo-
nuclease type IV (all from Sigma) in 10 ml HBSS. Secondly, the
cells were incubated in 2 mM EDTA in HBSS for 30 minutes
at 37°C. The supernatant was removed and placed on ice, and
the precipitate was incubated for 20 minutes at 37°C in 10 ml
HBSS containing 10 mg collagenase. The suspension was
washed with HBSS then passaged through a 23 gauge needle
three times. The cells were allowed to settle on ice for five
minutes, then the supernatants were washed twice with 5%
heat-inactivated FCS (GIBCO) in HBSS. These cells were then
suspended at 1.5 x 106 cells/mI in HBSS with 10% heat-
inactivated FCS then plated in slide-mounted, eight-chamber
tissue culture plates (Nunc, Inc., Naperville, Illinois, USA).
After an overnight incubation at 37°C in 5% CO2 chamber, the
slides were washed vigorously three times with RPM! to
remove any non-adherent cells. Staining with the monoclonal
antibody ED! (Bioproducts for Science) confirmed that > 95%
of the adherent cells were macrophages [25]. There were no
significant differences in the number of glomeruli isolated from
each stage of disease (approximately 4 x l0 per rat in each
case, with kidneys from rats with severe disease yielding an
average of 5 x 1O glomeruli per rat). However, as expected
from histologic studies [6], larger numbers of macrophages
were isolated from the moderate and severe stages of disease.
Means SEM were as follows: 9 x 106 0.5 x 106 macro-
phages per rat with severe chronic serum sickness; 5 x 106
0.4 x 106 per rat with moderate chronic serum sickness; 1.5 x
106 0.4 x 106 per rat with mild disease; 1 X 106 0.3 x 106
per normal, age-matched rat. The pattern of isolated glomerular
macrophage staining with the monoclonal antibodies ED2 and
ED3 were the same as previously reported in situ (Table 1) [61.
Specifically, approximately 40% of glomerular macrophages
from the moderate stage and 80% of glomerular macrophages
from the severe stage stained positively with ED3. Approxi-
mately 10% of glomerular macrophages from the severe stage
also stained positively with ED2.
Isolation of peritoneal macrophages
Resident peritoneal macrophages were obtained from normal
rats and rats at each stage of chronic serum sickness by
repeated gentle lavages of the peritoneal surface with RPM!
1640, after exsanguination of the animals by cardiac puncture
under anesthesia. The peritoneal cells were washed three times
in RPM! 1640 and suspended at 5 x l0 cells/ml. 250 pi of the
cell suspension were added to each chamber of slide-mounted,
eight-chamber tissue culture plates (Nunc) for phagocytosis and
rosetting experiments. Staining with the monoclonal antibody
ED! confirmed > 95% of these cells to be macrophages.
Peritoneal macrophages from normal rats stained positively
with ED! and ED2, but not ED3. However, >90% peritoneal
macrophages from rats at each stage of chronic serum sickness
stained positively for ED2 and ED3.
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Activated peritoneal macrophages were obtained from nor-
mal rats following intraperitoneal injection of 2.5 ml complete
Freund's adjuvant (CFA). Two weeks after the adjuvant injec-
tions, cells were harvested as described above for resident
macrophages, for use in phagocytosis and rosetting assays.
More than 90% of those peritoneal macrophages stained posi-
tively with ED1, ED2 and ED3.
Phagocytosis assays
Two hundred and fifty microliters of RPMI 1640 were added
to each chamber of the slide-mounted tissue culture plates on
which the macrophages were adhered. The cells were then
placed in a 37°C, 5% CO2 incubator for 30 minutes to allow for
equilibration. To assess Fcy receptor (FcyR)-mediated phago-
cytosis, 100 d of either E (to, determine nonspecific ingestion)
or EIgG were then added to each chamber and the plates were
centrifuged at 50 x g for five minutes at 4°C. After centrifuga-
tion, the cells were again placed in a 37°C incubator with 5%
CO2 and phagocytosis was allowed to proceed for one hour.
Phagocytosis was stopped by rinsing with 0°C lysing buffer to
remove non-internalized E. After two exposures to lysing
buffer, the cells were fixed with 1% glutaraldehyde and stained
with Giemsa. The percentage of macrophages in each chamber
that had ingested one or more E was determined by light
microscopy (l000x; oil immersion). The total number of E
ingested by these macrophages was also counted. The results of
the latter were expressed as the phagocytic index (P1), the total
number of ingested E per 100 macrophages.
Peritoneal macrophages, exposed to the three-step enzymatic
process used to isolate glomerular macrophages for phagocyto-
sis assays, did not differ from untreated cells in phagocytic
capacity or phenotypic marker expression. Therefore, subse-
quent experiments with peritoneal macrophages did not incor-
porate those procedures.
Rosetting assays
Macrophages were plated in slide-mounted, eight-chamber
tissue culture plates (Nunc), as described for the phagocytosis
assays (see above). After the addition of E (to determine
nonspecific binding) or EIgG, however, the cells were incu-
bated at 37°C with 5% CO2 for only 30 minutes to allow for
attachment but preclude ingestion. The slides were then rinsed
gently with RPMI x 3 to remove non-adherent E. The slides
were fixed with 1% glutaraldehyde, stained with Giemsa and
examined with a light microscope at 400 x. Macrophages with
3 erythrocytes attached were counted as positive, as previ-
ously described [26]. Exposure of peritoneal cells to the three-
step enzymatic process used to isolate glomerular macrophages
did not alter their rosetting capacity in pilot control studies.
Subsequent experiments did not include those enzymatic steps.
Statistical analysis
In all experiments each sample was run in triplicate. Six to
eight rats were used from each stage of chronic serum sickness
for glomerular macrophage experiments; three rats from each
stage for peritoneal macrophage experiments. Data are ex-
pressed as the mean SEM. Analysis of variance was used for
comparison of different progressive stages of chronic serum
sickness, followed by Scheffe (post-hoc) adjustments for the
data. P values  0.05 were considered significant.
Results
Phagocytic capacity
As expected, peritoneal macrophages from normal rats acti-
vated by complete Freund's adjuvant had a significantly in-
creased phagocytic capacity as compared to nonactivated nor-
mal peritoneal macrophages (53.6% vs. 25.3%; P = 0.02),
validating the experimental protocol. The phagocytic capacity
of glomerular macrophages from rats with mild chronic serum
sickness glomerulonephritis was indistinguishable from that of
normal pentoneal macrophages or normal glomerular macro-
phages (Fig. 1). It was, however, significantly less than that of
peritoneal macrophages from the same disease stage (31.9
1.8% vs. 61.7 2.0%, respectively; P < 0.01). Glomerular
macrophages from rats with moderate chronic serum sickness
glomerulonephritis had a significantly increased phagocytic
capacity compared with those from rats with mild disease (49.1
7.8% vs. 31.9 1.8%, respectively; P < 0.05). There was no
statistically significant difference in the phagocytic capacity of
peritoneal and glomerular macrophages from rats with moder-
ate disease. Glomerular macrophages isolated from rats which
had progressed to severe chronic serum sickness showed a
significant reduction (P < 0.0001) in phagocytic capacity com-
pared with cells from rats with moderate disease (22.2 2.9%
vs. 49.1 7.8%, respectively; Fig. 1). There was no difference
between the phagocytic capacity of glomerular macrophages
isolated from rats with severe chronic serum sickness glomer-
ulonephritis and resident peritoneal macrophages isolated from
normal rats. However, there was a significant decrease in
phagocytosis compared with peritoneal macrophages from an-
imals with severe disease. The phagocytic capacity of perito-
neal macrophages from rats at each stage of chronic serum
sickness was elevated compared with normal peritoneal mac-
rophages and equivalent to that of CFA-activated peritoneal
macrophages from normal rats (Fig. 1). Ingestion of nonop-
sonized E was < 3% in all experiments.
The phagocytic index was also increased for glomerular
macrophages from rats with moderate chronic serum sickness
and peritoneal macrophages from all three stages of disease
(Fig. 2). In addition, during moderate chronic serum sickness
nephritis, individual glomerular macrophages ingested a greater
number of opsonized erythrocytes than during the other stages
of disease (Table 2).
Macrophage Fc7R expression
EIgG rosette formation was measured as an index of macro-
phage FcyR expression. Normal resident peritoneal macro-
phages made significantly fewer rosettes than peritoneal and
glomerular macrophages obtained from animals at each stage of
chronic serum sickness (Fig. 3). There was no significant
difference between the number of rosettes formed with normal
glomerular and normal peritoneal macrophages. There was no
significant difference between the percent of glomerular or
peritoneal macrophages forming rosettes at each stage of
chronic serum sickness glomerulonephritis. Rosette formation
with nonopsonized E was <2% for all experiments.
Discussion
Intraglomerular macrophages have been well documented to
play a major role in the phagocytosis of immune complexes












Stage of chronic serum sickness
Fig. 1. Macrophage phagocytic capacity.
Glomerular macrophage phagocytic capacity
from mild chronic serum sickness nephritis
was not different from that of normal
peritoneal niacrophages. * P < 0.0001 vs. all 3
stages of chronic serum sickness; ** p
0.0001 vs. moderate and severe chronic serum
sickness; *** p < 0.0001 vs. moderate
chronic serum sickness. There were no
significant differences in the phagocytic
capacity of peritoneal macrophages from each
stage of chronic serum sickness. Symbols are:
(D) peritoneal; () glomerular.
Fig. 2. Macrophage phagocytic index. The
phagocytic index of normal glomerular
macrophages was no different than that of
macrophages from mild chronic serum
sickness. The phagocytic index of normal
peritoneal macrophages was significantly less
than at each stage of chronic serum sickness,
* P < 0.001; ** P < 0.01 vs. moderate
chronic serum sickness; *** p < 0.01 vs.
normal, mild and moderate chronic serum
sickness. Symbols are: (0) peritoneal; ()
glomerular.
present in the kidney [16, 17]. This function has generally been
thought to contribute to renal damage through the production
and/or release of proteinases, oxidants, prostaglandins, leuko-
trienes, cytokines, complement components and coagulation
factors [181. There has been much support for this position, as
it has been shown that depletion of macrophages prior to
induction of glomerulonephritis abrogates cellular infiltration
and the associated proteinuria [12, 13, 27]. Additionally, there is
documentation that intraglomerular macrophages are activated
in immune complex glomerulonephritis [6, 28]. It was therefore
not surprising to find increased phagocytic capacity of intra-
glomerular macrophages to levels equal to that of peritoneal




Number of EIgG permacrophage
1 2—4 5—7 8—10 >10
Normal 18 64 16 2 0
Mild 24 76 0 0 0
Moderate 18 45 19 12 6
Severe 94 5 1 0 0
Data are tabulated as mean percentage of phagocytic cells ingesting a
specified number of erythrocytes. The percentage of macrophages from
each stage of nephritis that actually ingested  1 erythrocyte is shown
in Figure 1.
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macrophages exposed to complete Freund's adjuvant. What
was unexpected, however, was the decreased glomerular mac-
rophage phagocytic capacity found as chronic serum sickness
progressed from the moderate to severe stage, in light of
phenotypic markers suggesting a possible increase in activation
state. It is unclear whether the decrease in phagocytic capacity
is the cause, or effect, of disease progression; an inability to
clear immune complexes deposited in the kidney has been
postulated to contribute to the progression of immune complex
nephritis [19, 20]. At the very least, the decrease in phagocy-
tosis may be considered an immunopathologic marker of gb-
merular macrophage dysfunction. This new data correlate a
functional anomaly with the phenotypic abnormalities previ-
ously reported (Table 1) [61.
Our data also show that this attenuation of glomerular mac-
rophage phagocytic capacity in the severe stage of chronic
serum sickness results from decreased FcyR function, not
decreased FcR expression. Gbomerular macrophage FcyR ex-
pression was elevated at each stage of nephritis compared with
both normal and activated peritoneal macrophages, yet only
30% of the glomerular macrophages which expressed Fc7R
demonstrated phagocytic activity in severe nephritis. This
compares with 53% for normal peritoneal macrophages, 55%
for normal glomerular macrophages, 67% for moderate glomer-
ular macrophages and 68% for severe peritoneal macrophages.
The combination of a larger percentage of phagocytic glomer-
ular macrophages and the greater number of erythrocytes
ingested by individual macrophages during moderate chronic
serum sickness nephritis may be a subtle indicator of "super-
activation." On the other hand, the low level of glomerular
macrophage phagocytic capacity during severe nephritis, de-
spite increased Fc7R expression, may either reflect the action
of a direct or indirect inhibitor of FcyR function, or a general-
ized exhaustion of cell energy sources due to continual immune
complex ingestion.
The production and possible role of the cytokines IL-i and
TNF in some animal models of glomerulonephritis, including
chronic serum sickness, has been previously reported [6, 29—
33]. Both of these soluble mediators may act to increase
macrophage phagocytic capacity [34]. However, other immu-
nologically active substances may also be secreted during the
severe stage of disease by the highly abnormal ED3 + glomer-
ular macrophages, or other glomerular cells, which counteract
the known stimulatory effects of IL-i and TNF. One potential
candidate for abrogation of an IL-i effect is IL-i receptor
antagonist (IL-iRa). Adherent IgG can induce production of
this cytokine by human mononuclear cells [35]. IL-IRa specif-
ically binds to the IL-l receptor, inhibiting the actions of IL-i
and could possibly result in a decrease of the high macrophage
phagocytic activity noted in the moderate stage of disease.
Studies are currently underway to test this hypothesis. Another
potential inhibitory candidate is IL-2, secreted by T cells, which
are known to be present during the moderate stage of disease
(Table 1) [6]. IL-2 has been shown to inhibit TNF stimulation of
phagocytosis in polymorphonuclear leukocytes [36], and a
similar phenomenon may be occurring with the glomerular
macrophages in this study.
Fc receptor function of peripheral human mononuclear cells
in patients with glomerulonephritis secondary to various auto-
immune diseases has been shown to be significantly reduced
both in vivo and in vitro [37—39]. Continual ingestion of immune
complexes with consequent exhaustion of cell energy source
has been postulated as the explanation for the impaired phago-
cytic capacity. Most of the glomerular macrophages in the
severe stage of chronic serum sickness have abnormal pheno-
types [6], which is suggestive of an activated metabolic state.
This lends support to the hypothesis of cell exhaustion. Addi-
tionally, circulating immune complexes are highest in the mild
stage and lowest in the severe stage [40]. However, it is unclear
whether gbomerular macrophage phagocytic capacity is reflec-
tive of peripheral mononuclear cell function as chronic serum
sickness progresses, since a large number of the gbomerular
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Stage of chronic serum sickness
Fig. 3. Macrophage rosette formation.
Glomerular and peritoneal macrophages from
each stage of chronic serum sickness nephritis
formed significantly more rosettes than normal
peritoneal macrophages, * P < 0.05. Symbols
are: (D) peritoneal; () glomerular.
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macrophages arise by local proliferation [41]. In addition, the
phagocytic capacity of peritoneal macrophages from animals
with severe disease is not impaired, as compared with other
disease stages or normal animals. It would therefore appear that
there is local, rather than general inhibition of macrophage
phagocytic function. This type of differential response at sites
of local inflammation has been described in other situations.
Differences in local expression of complement genes in a
munne model of lupus nephritis has been reported [42], and
recently, differences in the response of synovial fluid macro-
phages and peripheral blood monocytes to IL-4 have been
reported [43]. A recent report from our laboratory indicates that
the expression of phenotypic markers of macrophage activation
can be prevented in chronic serum sickness by treatment with
cyclosporin A [44]. The effect of this treatment on mononuclear
cell phagocytic function could be used to evaluate the activa-
tion/exhaustion hypothesis.
In summary, macrophages present in the glomerulus during
the severe stage of chronic serum sickness have decreased
phagocytic capacity when compared to those present during the
moderate stage. On the other hand, peritoneal macrophages
from rats with severe chronic serum sickness showed no such
attenuation. This may indicate that depression of glomerular
macrophage function can contribute to disease progression in
this model. The presence of glomerular mononuclear cells may
have multiple effects (some harmful and some beneficial), and in
all likelihood, there are multifactorial causes for the attenuated
phagocytic capacity described here. Studies are ongoing to test
the hypotheses discussed.
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